{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:17:45Z","timestamp":1793852265438,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1053\/ctrv.2000.0210","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T13:54:50Z","timestamp":1032443690000},"page":"165-176","source":"Crossref","is-referenced-by-count":1591,"title":["Metastatic bone disease: clinical features, pathophysiology and treatment strategies"],"prefix":"10.1053","volume":"27","author":[{"given":"R.E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/ctrv.2000.0210_RF1","unstructured":"Rubens, R. D. Coleman, R. E. Bone metastases. Abeloff, M, DArmitage, J, OLichter, A, SNiederhuber, J, E, Clinical Oncology, Churchill, New York: Livingstone, 2000, 836, 871"},{"key":"10.1053\/ctrv.2000.0210_RF2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-16-1-38","article-title":"The role of the vertebral veins in the metastatic process","volume":"16","author":"Batson","year":"1942","journal-title":"Ann Intern Med"},{"key":"10.1053\/ctrv.2000.0210_RF3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1464-410X.1985.tb07040.x","article-title":"Generalised increase in bone resorption in carcinoma of the prostate","volume":"57","author":"Urwin","year":"1985","journal-title":"Br J Urol"},{"key":"10.1053\/ctrv.2000.0210_RF4","series-title":"Rubens RD, Mundy GR eds Cancer and the Skeleton","article-title":"Biochemical markers of malignant bone disease","author":"Coleman","year":"2000"},{"key":"10.1053\/ctrv.2000.0210_RF5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1053\/ctrv.1999.0133","article-title":"Use of bisphosphonates for the treatment of bone metastasis in experimental animal models","volume":"25","author":"Yoneda","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/ctrv.2000.0210_RF6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/ctrv.1999.0143","article-title":"Tumour progression and angiogenesis in bone metastases from breast cancer: new approaches to an old problem","volume":"26","author":"van der Pluijm","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/ctrv.2000.0210_RF7","first-page":"613","article-title":"Prognostic factors in stage D2 prostate cancer: important implications for future trials: results of a Co-operative Intergroup Study (INT 0036)","volume":"21","author":"Eisenberger","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF8","series-title":"Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE eds, Clinical Oncology, 2nd edn","article-title":"Multiple myeloma and related disorders","author":"Kyle","year":"2000"},{"key":"10.1053\/ctrv.2000.0210_RF9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following recurrence from breast cancer","volume":"17","author":"Coleman","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0277-5379(90)90080-D","article-title":"Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival","volume":"26","author":"O\u2019Reilly","year":"1990","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0889-8588(05)70364-6","article-title":"How is androgen dependent metastatic prostate cancer best treated?","volume":"10","author":"Robson","year":"1996","journal-title":"Haematol Oncol Clinics North Am"},{"key":"10.1053\/ctrv.2000.0210_RF13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","article-title":"C-reactive protein and 2 microglobulin produce a simple and powerful myeloma staging system","volume":"80","author":"Bataille","year":"1992","journal-title":"Blood"},{"key":"10.1053\/ctrv.2000.0210_RF14","series-title":"Tumour bone diseases and osteoporosis in cancer patients","first-page":"457","article-title":"Bisphosphonates in the treatment of multiple myeloma","author":"Kanis","year":"2000"},{"key":"10.1053\/ctrv.2000.0210_RF15","series-title":"Clinical Oncology","first-page":"719","article-title":"Hypercalcaemia","author":"Morton","year":"2000"},{"key":"10.1053\/ctrv.2000.0210_RF16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00003086-198912000-00027","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathological fracture","volume":"249","author":"Mirels","year":"1989","journal-title":"Clin Orthop Rel Res"},{"key":"10.1053\/ctrv.2000.0210_RF17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/ana.410200608","article-title":"Early detection of spinal epidural metastases: the role of myelography","volume":"20","author":"Rodichok","year":"1986","journal-title":"Ann Neurol"},{"key":"10.1053\/ctrv.2000.0210_RF18","series-title":"Rubens RD, Mundy GR eds, Cancer and the Skeleton","article-title":"Spinal stabilisation","author":"Harrington","year":"2000"},{"key":"10.1053\/ctrv.2000.0210_RF19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1","article-title":"Radiation of bone metastases: conventional techniques and the role of systemic radiopharmaceuticals","volume":"80","author":"Janjan","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium89in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF21","first-page":"44","article-title":"Clinical experience with strontium89in prostatic and breast cancer patients","volume":"20","author":"Robinson","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF22","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0959-8049(97)00155-X","article-title":"A dose-controlled study of153Sm-Ethylenediaminetetramethylenephosphate (EDTMP) in the treatment of patients with painful bone metastases","volume":"33","author":"Resche","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1023\/A:1012157212793","article-title":"Inhibition of growth of Dictyostelium discoideum amoeboe by bisphosphonates is dependent on cellular uptake","volume":"14","author":"Rogers","year":"1997","journal-title":"Pharmacol Res"},{"key":"10.1053\/ctrv.2000.0210_RF24","doi-asserted-by":"crossref","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bishosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(96)90020-1","article-title":"Use of bisphosphonates in cancer patients","volume":"22","author":"Body","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/ctrv.2000.0210_RF27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","article-title":"High-dose intravenous pamidronate for metastatic bone pain","volume":"70","author":"Purohit","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomised controlled trial of intravenous clodronate in metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"J Pain Symptom Manag"},{"key":"10.1053\/ctrv.2000.0210_RF29","first-page":"575a","article-title":"Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone","volume":"18","author":"Body","year":"1999","journal-title":"Proc ASCO"},{"key":"10.1053\/ctrv.2000.0210_RF30","first-page":"586a","article-title":"Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases","volume":"88","author":"Berenson","year":"1998","journal-title":"Blood"},{"key":"10.1053\/ctrv.2000.0210_RF31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF32","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double blind controlled trial of clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/ctrv.2000.0210_RF35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/ctrv.2000.0210_RF36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/02841869609083974","article-title":"Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial","volume":"35","author":"Hultborn","year":"1996","journal-title":"Acta Oncologica"},{"key":"10.1053\/ctrv.2000.0210_RF37","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: a randomised, placebo- controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF39","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.2000.0210_RF40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.2000.0210_RF41","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF42","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2000.0210_RF43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"141","author":"Smith","year":"1989","journal-title":"J Urol"},{"key":"10.1053\/ctrv.2000.0210_RF45","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.1999.14.9.1557","article-title":"A dose-finding study of zoledronate in hypercalcaemic cancer patients","volume":"14","author":"Body","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1053\/ctrv.2000.0210_RF46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF47","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: a randomised study in premenopausal patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF48","first-page":"468a","article-title":"Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer","volume":"17","author":"Powles","year":"1998","journal-title":"ASCO Proc"},{"key":"10.1053\/ctrv.2000.0210_RF49","first-page":"130a","article-title":"Goerner R et al. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone meta stases","volume":"16","author":"Diel","year":"1997","journal-title":"ASCO Proc"},{"key":"10.1053\/ctrv.2000.0210_RF50","doi-asserted-by":"crossref","unstructured":"Saarto, T. Blomqvist, C. Virkkunen, P. Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletla metastases in node-positive breast cancer patients: 5 year results of a randomised conrolled trial. J Clin Oncol 2001, 19, 10, 17.","DOI":"10.1200\/JCO.2001.19.1.10"},{"key":"10.1053\/ctrv.2000.0210_RF51","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2000.0210_RF52","series-title":"Rubens RD, Mundy GR eds, Cancer and the Skeleton","article-title":"Bone metastases\u2014incidence and complications","author":"Rubens","year":"2000"},{"key":"10.1053\/ctrv.2000.0210_RF53","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment","volume":"ii","author":"van Holten-Verzantvoort","year":"1987","journal-title":"Lancet"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573720090210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573720090210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T05:02:58Z","timestamp":1682139778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573720090210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["S030573720090210X"],"URL":"https:\/\/doi.org\/10.1053\/ctrv.2000.0210","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}